PRAME-Targeted Agent Shows Activity in Pretreated Metastatic Melanoma
Source: Cancer Network, October 2024
Phase 1b findings may affirm the therapeutic potential of IMA203 for patients with previously treated metastatic melanoma.
Treatment with IMA203, an investigational T-cell therapy targeting preferentially expressed antigen in melanoma (PRAME), demonstrated clinical activity among a small cohort of patients with previously treated metastatic melanoma, according to a presentation on data from a phase 1 trial (NCT03686124).
Findings highlighted at the 2024 Society for Melanoma Research Congress showed a confirmed objective response rate (ORR) of 54% (n = 14/26) and a median duration of response (DOR) of 12.1 months (range, 4.2 to 25.5+). Of note, 7 of 14 patients with a confirmed response had ongoing responses at the time of the analysis.